ARCHIVES

BMS, Exelixis To Collaborate On Drug Development.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Avon Awards $50 Million To NCI And Three Centers.

October 12, 2001

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

As Zeneca Buys Salick, Implications For Oncology Managed Care Uncertain

April 4, 1997

Reaction To PSA Guideline Muffled Compared to 2009 Mammography Guideline

October 14, 2011

RFA On Breast Tumor Factors Patients Survival

June 20, 1980

New Policy on Minor Changes in Trials Requires Halt in Patient Enrollment.

April 25, 2008